$CODX SEC Filings

As previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). Because a quorum was not present or represented, the Company was una...

THIS ATM WATERFALL DISTRIBUTION AGREEMENT (“Agreement”) is made and entered into as of October 9, 2026 by and among Co-Diagnostics, Inc., a Utah corporation (the “Company”) and J.J. Astor & Co., a Utah corporation (“Astor” or the “Lender...

This Loan Agreement (this “Agreement”) is dated as of October 9, 2026 (the “Agreement Date”) and is made and entered into between Co-Diagnostics, Inc., a Utah corporation (the “Company”), and J.J. Astor & Co., a Utah corporation ( “Astor...

As previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). However, the Company did not achieve a quorum and therefore was unab...

As previously announced on September 4, 2026, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). However, the Company did not achieve a quorum a...

Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola

On September 16, 2026, Co-Diagnostics, Inc. (the “Company”) will host an investor and analyst presentation regarding, among other matters, the Company’s collaboration with ReadyGo Diagnostics Ltd., the Company’s Co-Dx PCR platform and re...

In August 2026, Co-Diagnostics, Inc. (the “Company”) entered into a material transfer agreement with ReadyGo Diagnostics Ltd (“ReadyGo”) to evaluate the potential compatibility of certain ReadyGo sample collection and preparation technol...

Holds 3,657 shares of Common Stock